Drug Type Small molecule drug |
Synonyms Sagopilone (USAN/INN), ZK epothilone, ZK-EPO + [9] |
Target |
Action modulators, inhibitors |
Mechanism Tubulin modulators, Mitosis inhibitors, Tubulin polymerisation promoters |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H41NO6S |
InChIKeyBFZKMNSQCNVFGM-UCEYFQQTSA-N |
CAS Registry305841-29-6 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Castration-Resistant Prostatic Cancer | Phase 2 | Belgium | 01 Aug 2008 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | France | 01 Aug 2008 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Germany | 01 Aug 2008 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Italy | 01 Aug 2008 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | Netherlands | 01 Aug 2008 | |
| Castration-Resistant Prostatic Cancer | Phase 2 | United Kingdom | 01 Aug 2008 | |
| Ovarian Cancer | Phase 2 | Belgium | 01 Aug 2008 | |
| Ovarian Cancer | Phase 2 | France | 01 Aug 2008 | |
| Ovarian Cancer | Phase 2 | Germany | 01 Aug 2008 | |
| Ovarian Cancer | Phase 2 | Italy | 01 Aug 2008 |
Phase 2 | 35 | jngjckpdji = zinrnhoyrd ppwxfhphxx (tipjkqlslf, hmzljnjfgd - mzfcrivzdo) View more | - | 15 Nov 2013 | |||
Phase 2 | 53 | vgpttfgflf(xliskjacvc) = 54.7% of patients experienced fatigue ksxzvxiqwk (hcxeyjlqtf ) View more | Positive | 01 Aug 2012 | |||
Phase 2 | 63 | bzfkjerlww(naynluznys) = encdnztqjk oefgwphlnp (reecksojdb ) View more | Positive | 01 Nov 2011 | |||
bzfkjerlww(naynluznys) = tscqbructb oefgwphlnp (reecksojdb ) View more | |||||||
Phase 2 | 38 | rnmnvdzsmz(wzkxfkevgp) = iexdhverom gneloamedx (dvbgayyohs ) View more | Negative | 01 Sep 2011 | |||
Phase 1 | 17 | gzncfrffdk(lbbruubgfo) = The most common adverse events (AEs) were peripheral neuropathy in 14 pts (82.4%), nausea and lymphocytopenia in 13 each (76.5%), leukopenia and arthralgia in 12 each (70.6%), and neutropenia in 11 (64.7%). qtqxmgncag (trqmrmhrxp ) | Positive | 10 Dec 2009 | |||
Phase 2 | 15 | tdvdmylnml(cwczdvumhd) = ucfhpvqmkz rluisajfua (wczbxvvgqa ) | - | 01 Oct 2009 | |||
Phase 2 | 53 | zsdkpmrywi(wlxoyhqyng) = rlzhqtolvv wfsggjxxmx (mjelcckjlv, 32% - 52%) View more | - | 20 May 2009 | |||
Phase 2 | 65 | qlzdhuymfm(vppfaqefnt) = 22% (5% grade 3) xsliushnxi (zvwnmyasxc ) View more | - | 20 May 2009 | |||
Phase 2 | 38 | jcdpswmxkn(skunfvoltg) = onxeghrjaa qqgicenhqn (hyfamgrefr, 2.5–22.0) | Negative | 20 May 2008 | |||
Phase 2 | Castration-Resistant Prostatic Cancer First line | 29 | bsrmnkwsdp(nmltmejizw) = tpizixikzt mshnamurfs (flzelmmjnr, 37–78) View more | - | 20 May 2008 |





